Correction to: Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis

Correction to: BMC Infect Dis 21, 222 (2021)

https://doi.org/10.1186/s12879-021-05850-0

Following publication of the original article [1], the authors identified errors in Figs. 3a, b and 4. The correct figures are given below.

Fig. 3.

Efficacy Results. a VS Risk Difference (RE model). b CD4 difference (FE model)

Fig. 4.

Odds of all-cause discontinuation (FE model)

The original article has been corrected.